Enzymatica AB (publ) (OM: ENZY)
Health Care · Pharmaceuticals · SE
Skr1.90
+2.15% today · -20.5% 1Y
Enzymatica AB (publ) (OM: ENZY) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $47.68M and employs 18 people.
Over the last twelve months the share price has lost 20.5%, trading between 1.60 and 3.40.
Tweenvest scores Enzymatica AB (publ) across four factors: quality 33/100, value 62/100, growth 31/100. Its strongest factor is value.
ENZY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $47.68M
- Revenue (TTM)
- $5.36M
- P/E
- —
- EPS
- -0.19
- Dividend yield
- —
- Beta (5Y)
- -0.40
- 52-week high
- Skr3.40
- 52-week low
- Skr1.60
- Avg volume (3M)
- —
- Shares outstanding
- 242.74M
- Employees
- 18
- Next earnings
- —
About Enzymatica AB (publ)
Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.
- ISIN
- SE0003943620
- Founded
- 2007
- Listed since
- Jun 14, 2011
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.